The European Association of Nuclear Medicine (EANM) recommends 18F-FDG PET/CT for differentiated thyroid cancer (DTC) patients with rising Tg levels to aid in detecting recurrent/metastatic disease and determining the tumor’s biological behavior [2]. The gene discussed is TG; the disease is metastatic neoplasm.